New Surgeon General’s Report Targets Teen Smoking Among Minorities

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 6
Volume 7
Issue 6

WASHINGTON--Minority teenagers are smoking more, and this threatens to undermine the progress against lung cancer among minority populations that was made during the early 1990s.

WASHINGTON--Minority teenagers are smoking more, and this threatens to undermine the progress against lung cancer among minority populations that was made during the early 1990s.

David Satcher, MD, in his first report as Surgeon General, focused on four racial and ethnic minority groups: African-Americans, American Indians/Alaska Natives, Asian American/Pacific Islanders, and Hispanics.

Rates of tobacco use among adolescents in these racial and ethnic minority groups have begun to rise rapidly, especially among African-American youths, who had the greatest decline during the 1970s and 1980s but the steepest increase in use in the 1990s--80% over the last 6 years, three times higher than the increase among white teens.

Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.
Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.